Strides gets European regulatory nod for oral dosage cancer facility
01 Jul 2011
Onco Therapies Limited (OTL), a division of Agila, a wholly owned subsidiary of Strides Arcolab Limited, today said that it had received European approval for its oral dosage oncology facility in Bangalore.
The regulatory approval covers OncoTherapies's tablet and hard gelatine capsules.
The Injectable facility within the oncology complex has already been approved by all major regulatory agencies. The facility is now amongst a few European approved oral dosage oncology plants worldwide.
The company expects to commercialise two products in Europe during Q3 2011.
Venkat Iyer, CEO, Agila Specialties, said, ''This further consolidates our global strategy of emerging as a leading provider of oncology drugs.''
The state-of-the-art oncology complex that was established in 2009, manufactures injectables, tablets and softgels for oral consumption in the oncology drugs segment and has also been approved by all other major regulatory authorities, enabling the company to enter global markets.
.webp)
.webp)
.webp)
